Coherus BioSciences (CHRS) Reports Q2 Loss of $1.56
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.24 -4.62%
Revenue Growth %: +37.8%
Financial Fact:
Gross profit: 261.73M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +37.8%
Financial Fact:
Gross profit: 261.73M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($1.56), versus ($5.90) reported last year. Revenue for the quarter came in at $6.87 million, versus $4.46 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Espey Manufacturing (ESP) Tops Q4 EPS by 24c
- AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
